News

As part of the deal, UCB will receive the world-wide exclusive license to develop and commercialize Neuropore’s new small molecule NPT200-11in all indications. NPT200-11 that targets pathogenic alpha-synuclein

ATB-346 targets the need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. According to the company, safety concerns centered on the finding of significant

Of the total amount, $5.65m will be spent on Coldstream facility on the Research Park Campus of the University, while the remaining will be used to acquire the

The combination has been approved with or without ribavirin (RBV) for these patients, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver

NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at

The IMI grant will be used to accelerate the development and testing of JNJ’s vaccine regimen through a newly formed consortium that includes Janssen, the London School of

Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthalechoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and

The Phase II results showed that mipsagargin appears to be effective and is well-tolerated by HCC patients. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA), which is highly

The company said that advancement to the predictive biomarker expansion stage triggered a $5m milestone from its partner GlaxoSmithKline (GSK). The expansion stage of the anti-Notch1 Phase Ia